Goldman Sachs Upgrades CA (CA) to Neutral
Tweet Send to a FriendGet Alerts CA Hot Sheet
Price: $27.71 +0.07%
Rating Summary:
1 Buy, 12 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 21 | Down: 43 | New: 13
Rating Summary:
1 Buy, 12 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 21 | Down: 43 | New: 13
Trade CA Now!
Goldman Sachs upgraded CA (NASDAQ: CA) from Sell to Neutral, while maintaining their $25 price target.
The analyst notes shares are trading down 1% year-to-date, versus a 5% rise in the S&P 500, and are near a historic low multiple. The firm said the shares' risk/reward profile has improved.
Goldman sees the potential for revenue growth to show some acceleration in FY12 "as bookings from the downturn period start to roll off the P&L and bookings from the recovery period start to roll on."
For more ratings news on CA click here and for the rating history of CA click here.
Shares of CA closed at $24.18 yesterday, with a 52 week range of $17.70-$25.68.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The analyst notes shares are trading down 1% year-to-date, versus a 5% rise in the S&P 500, and are near a historic low multiple. The firm said the shares' risk/reward profile has improved.
Goldman sees the potential for revenue growth to show some acceleration in FY12 "as bookings from the downturn period start to roll off the P&L and bookings from the recovery period start to roll on."
For more ratings news on CA click here and for the rating history of CA click here.
Shares of CA closed at $24.18 yesterday, with a 52 week range of $17.70-$25.68.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Goldman Sachs Upgrades Abbott Labs (ABT) to Buy
- Maxim Group Upgrades J. C. Penney (JCP) to Buy, Sees 50% Upside
- UPDATE: Leerink Swann Upgrades Bristol-Myers Squibb Co. (BMY) to Outperform
Create E-mail Alert Related Categories
UpgradesRelated Entities
Goldman Sachs, Standard & Poor'sLogin with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

